BioXcel Therapeutics (BTAI) to prioritize high-potential agitation market opportunities for BXCL501 in bipolar disorders, schizophrenia, and Alzheimer’s disease

Go back to BioXcel Therapeutics (BTAI) to prioritize high-potential agitation market opportunities for BXCL501 in bipolar disorders, schizophrenia, and Alzheimer’s disease
(NASDAQ: BTAI) Delayed: 1.26 -0.04 (3.08%)
Previous Close $1.30    52 Week High
Open $1.28    52 Week Low
Day High $1.33    P/E N/A 
Day Low $1.25    EPS
Volume 724,073